References

evrazkar

Евразийский Кардиологический Журнал

Eurasian heart journal

2225-16852305-0748

Евразийская ассоциация кардиологов

10.38109/2225-1685-2014-2-44-48

evrazkar-5584

Research Article

ОРИГИНАЛЬНЫЕ СТАТЬИ

ORIGINAL PAPERS

СКОРОСТЬ КЛУБОЧКОВОЙ ФИЛЬТРАЦИИ КАК ПОКАЗАТЕЛЬ ПОРАЖЕНИЯ ПОЧЕК У БОЛЬНЫХ С АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ

GLOMERULAR FILTRATION RATE AS A MARKER OF KIDNEY DAMAGE IN PATIENTS WITH ARTERIAL HYPERTENSION

Зелвеян

Парунак Арутюнович

Zelveian

P. H.

zelveian@hotmail.com

Дгерян

Лусине Гагиковна

Dheryan

L. G.

noemail@neicon.ru

Центр превентивной кардиологии; Национальный институт здравоохранения им. академика С. Авдалбекяна, МЗ РАРоссияCenter of Preventive Cardiology; National Institute of Health after academician S. Avdalbekyan, MoH RARussian Federation

ЕГМУ имени М. ГерациРоссияYSMU after M. HeratsiRussian Federation

2014

30062014

024448

2014

Зелвеян П.А., Дгерян Л.Г.

Zelveian P.H., Dheryan L.G.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.heartj.asia/jour/article/view/5584

В последние годы во всем мире отмечается прогрессивное увеличение числа больных с хронической почечной недостаточностью (ХПН), и, немаловажно, что этот рост не имеет тенденции к замедлению в будущем. В многочисленных исследованиях доказана четкая связь между выраженностью артериальной гипертензии (АГ), длительностью ее существования и частотой развития ХПН. В этом аспекте скорость клубочковой фильтрации (СКФ) при АГ отражает ранние, промежуточные, а также поздние стадии поражения почек, причем в этих условиях изменения СКФ носят разнообразный характер. Так, в условиях АГ на ранних стадиях поражения почек отмечается повышение СКФ, а на более поздних стадиях - понижение. При АГ СКФ является также предиктором поражения других органов-мишеней и сердечно-сосудистой заболеваемости и смертности. Таким образом, оценка СКФ должна более широко внедряться в клиническую практику с целью обнаружения других сердечно-сосудистых факторов риска и ассоциированных клинических состояний, а также продолжительного мониторинга и предотвращения поражений органов-мишеней.

In the recent years there is a tendency for progressive increase in the number of patients with chronic kidney failure (CKF) in the world and, importantly, that this growth does not tend to slow down in the future. Numerous studies have proven a clear relationship between the degree and duration of arterial hypertension (AH) and incidence of CKF. in this view during AH glomerular filtration rate (GFR) reflects early, intermediate and also late stages of kidney damage and in this case changes of GFR have diverse character. so, an increase of absolute values of GFR is typical for early stages of AH and a decrease of GFR is typical for the late stages of AH. in the same time during AH GFR can be presented as a predicting risk factor for other target organ damage and cardiovascular morbidity and mortality development as well. Thus the evaluation of GFR should be more widely introduced in the clinical practice with the purpose of revelation of other cardiovascular risk factors and associated pathological conditions, continuous monitoring and prevention of target organ damage.

артериальная гипертензияхроническая почечная недостаточностьскорость клубочковой фильтрацииarterial hypertensionchronic kidney failureglomerular filtration rate

References1

Costanzo S., Di Castelnuovo A., Zito F., et al. Prevalence, awareness, treatment and control of hypertension in healthy unrelated male-female pairs of European regions: the dietary habit profile in European communities with different risk of myocardial infarction: the impact of migration as a model of gene environment interaction project. J Hypertens 2008; 26: 2303-11.

Kearney P., Whelton M., Reynolds K., et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22(1): 11-9.

D’Agostino R., Vasan R., Pencina M., et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117: 743-53.

Kearney P., Whelton M., Reynolds K., et al. Global burden of hypertension: Analysis of worldwide data. Lancet 2005; 365: 217-23.

Pereira M., Lunet N., Azevedo A., et al. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens 2009; 27(5): 963-75.

Valderrabano F., Gomez-Campedra F., Jones E. Hypertension as a cause of end-stage renal disease: lessons from international registries. Kidney Int 1998; 68: Suppl.: S60-6.

Coresh J., Wei G., McQuillan G., et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States, findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2001; 161: 9: 1207-16.

Sharma A. Renal involvement in hypertensive cardiovascular disease. European Heart Journal 2003; 5: Suppl. F: F12-8.

Sarnak M., Levey A. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000; 35: 4: Suppl.1: S17-31.

Tsioufis C., Tsiachris D., Kasiakogias A., et al. Preclinical cardiorenal interrelationships in essential hypertension. Cardiorenal Med 2013; 3(1): 38-47.

Wang J., Xiong X., Liu W. Discussion on treatment of hypertension by tonifying kidney. Zhongguo Zhong Yao Za Zhi 2013; 38(9): 1277-9.

Ruilope L., Zanchetti A., Julius S., et al. Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial. Journal of Hypertension 2007; 25: 7: 1473-79.

García-Donaire J., Ruilope L. Cardiovascular and Renal Links along the Cardiorenal Continuum. Int J Nephrol 2011; 2011: 975782.

Ruilope L., Bakris G. Renal function and target organ damage in hypertension. Eur Heart J 2011; 32(13): 1599-604.

Cerasola G., Guarneri M., Cottone S. Inflammation, oxidative stress and kidney function in arterial hypertension. G Ital Nefrol 2009; 26: Suppl 46: 8-13.

Edwards R. Segmental effects of norepinephrine and angiotensin II on isolated renal microvessels. Am J Physiol 1983; 244: 5: F526-34.

Franco M., Tapia E., Bautista R., et al. Impaired pressure natriuresis resulting in salt-sensitive hypertension is caused by tubulointerstitial immune cell infiltration in the kidney. Am J Physiol Renal Physiol 2013; 1: 304(7): F982-90.

Буланова М.Н., Конечная Е.Я., Нанчикеева М.Л. Показатели внутрипочечной гемодинамики у больных с впервые выявленной артериальной гипертонией. Эхография 2002; 3: 42-6.

Ruilope L., Alcazar J., Rodicio J. Renal consequences of arterial hypertension. J Hypertens 1992; 10: Suppl 7: S85-S90.

Dworkin L., Hostetter T., Rennke H., Brenner B. Hemodynamic basis for glomerular injury in rats with desoxycorticosterone-salt hypertension. J Clin Invest 1984; 73(5): 1448-61.

Nanchikeeva M., Kozlovskaia L., Rameev V. Determination of urinary markers of proteolysis/fibrinolysis and fibroangiogenesis in the kidney in hypertensive patients Ter Arkh 2011; 83(6): 23-7.

Нанчикеева М.Л., Конечная Е.Я., Буланова М.Н. Возможности ранней диагностики поражении почек у больных гипертонической болезнью. Терапевтический архив 2004; 9: 29-34.

Нанчикеева М.Л. Состояние внутрипочечной гемодинамики у больных гипертонической болезнью. Клиническая медицина. Вопросы клиники, диагностики, профилактики и лечения. Межвузоский сборник стран СНГ.2007; 15: 100-10.

Mennuni S., Rubattu S., Pierelli G., et al. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. J Hum Hypertens. 2013; 27: doi: 10.1038.

Rodríguez-Iturbe B., Franco M., Tapia E., et al. Renal inflammation, autoimmunity and salt-sensitive hypertension. Clin Exp Pharmacol Physiol 2012; 39(1): 96-103.

Lopez-Vargas P., Tong A., Sureshkumar P., et al. Prevention, detection and management of early chronic kidney disease: a systematic review of clinical practice guidelines. Nephrology (Carlton) 2013; doi: 10.1111.

Chang A., Kramer H. Should eGFR and Albuminuria Be Added to the Framingham Risk Score? Chronic Kidney Disease and Cardiovascular Disease Risk Prediction. Nephron Clin Pract 2011; 119: 171-178.

Mancia G., Fagard R., Narkiewicz K., et al. ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Journal of Hypertension 2013; 31: 1281-1357.

Nannipieri M., Rizzo L., Rapuano A., et al. Increased transcapillary escape of albumin in microalbuminuric type II diabetic patients. Diabetes Care 1995; 18: 1-9.

Mimran A., Ribstein J., DuCailar G. Is microalbuminuria a marker of early intrarenal vascular dysfunction in essential hypertension? Hypertension 1994; 23: 1018-21.

Reid M., Bennett F., Wilks R., Forrester T. Microalbuminuria, renal function and waist: hip ratio inblack hypertensive Jamaicans. J Hum Hypertens 1998; 12: 221-7.

Pontremoli R., Viazzi F., Martinoli C., et al. Increased renal resistive index in patients with essential hypertension: a marker of target organ damage. Nephrol Dial Transplant 1999; 14: 360-5.

Losito A., Fortunati F., Zampi I., Del Favero A. Impaired renal functional reserve and albuminuria in essential hypertension. BMJ 1988; 296: 1562-4.

Pinto-Sietsma S., Janssen W., Hillege H., et al. Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. J Am Soc Nephrol 2000; 11: 1882-8.

Hoy W., Wang Z., VanBuynder P., et al. The natural history of renal disease in Australian Aborigines. Part 1. Changes in albuminuria and glomerular filtration rate over time. Kidney Int 2001; 60: 243-8.

Karam Z., Tuazon J. Anatomic and physiologic changes of the aging kidney. Clin Geriatr Med. 2013; 29(3): 555-64.

Ribstein J., Du Cailar G., Mimran A. Glucose tolerance and age-associated decline in renal function of hypertensive patients. J Hypertens 2001; 19: 2257-64.

Delanaye P., Schaeffner E., Ebert N., et al. Normal reference values for glomerular filtration rate: what do we really know? Nephrol Dial Transplant 2012; 27(7): 2664-72.

Fesler P., Du Cailar G., Ribstein J., Mimran A. Left ventricular remodeling and renal function in never-treated essential hypertension. J Am Soc Nephrol 2003; 14(4): 881-7.

Fesler P., Ribstein J., du Cailar G., Mimran A. Determinants of cardiorenal damage progression in normotensive and nevertreated hypertensive subjects. Kidney Int 2005; 67: 1974-9.

Hemmelgarn B., Manns B., Lloyd A., et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010; 303: 423-9.

Mann J., Gerstein H., Pogue J., et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-36.

Muntner P., He J., Hamm L., et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13: 745-753.

Matsushita K., van der Velde M., Astor B., et al: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-81.

Mule G., Cottone S., Cusimano P., et al. Unfavourable interaction of microalbuminuria and mildly reduced creatinine clearance on aortic stiffness in essential hypertension. Int J Cardiol 2010; 19; 145(2): 372-5.

Astor B., Matsushita K., Gansevoort R. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney International 2011; 79,1331-40.

Reboldi G., Gentile G., Angeli F., et al. Microalbuminuria and hypertension. Minerva Med. 2005; 96(4): 261-75.

The authors declare that there are no conflicts of interest present.